CYP2C18 GWAS Links CYP2C19 to Plavix Response; Randomized-Controlled Trial, PGx Consortium to Come Premium Following the GWAS, researchers plan to conduct a prospective, randomized-controlled trial and form a pharmacogenomics consortium specifically focused on validating and discovering new gene-response variants for clopidogrel. Breaking News 23andMe Receives Warning of Nasdaq Listing Noncompliance US PTAB Invalidates 10x Genomics Single-Cell Patent Biognosys, Thermo Fisher Ink Reselling Deal for Spectronaut Proteomics Software Genetics of Anxiety Disorder Unraveled in Multiomic, Multi-Ancestry Study 23andMe Independent Board Directors Resign, Citing Lack of Progress on Take-Private Proposal
